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Abstract Amino acids in the K- and Q-subunits contribute to the
benzodiazepine binding site of GABAA-receptors. We show that
the mutation of a conserved histidine residue in the N-terminal
extracellular segment (K1H101R, K2H101R, K3H126R, and
K5H105R) results not only in diazepam-insensitivity of the
respective KxL2,3Q2-receptors but also in an increased potentia-
tion of the GABA-induced currents by the partial agonist
bretazenil. Furthermore, Ro 15-4513, an inverse agonist at wild-
type receptors, acts as an agonist at all mutant receptors. This
conserved molecular switch can be exploited to identify the
pharmacological significance of specific GABAA-receptor sub-
types in vivo.
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1. Introduction
Classical benzodiazepines (BZ) such as diazepam are in
wide clinical use as anxiolytics, hypnotics, myorelaxants and
anticonvulsants. These activities are based on the enhance-
ment of GABAergic transmission at BZ-sensitive GABAA-re-
ceptors [1], which are composed of an K-subunit variant (K1,
K2, K3, or K5) in combination with a L-subunit (L1^3) and a
Q-subunit (Q1^3) [2^4]. The receptor subtypes K1L2,3Q2,
K2L2,3Q2, K3L2,3Q2 and K5L2,3Q2 are considered to be the
major mediators of BZ actions in the brain [5]. To identify
the pharmacological signi¢cance of individual receptor sub-
types, point mutations were sought by which individual recep-
tor subtypes might be rendered diazepam-insensitive in vivo.
In previous mutational analyses, a histidine to arginine sub-
stitution in position 101 of the K1-subunit (K1H101R) strongly
reduced the diazepam response of the recombinant K1L2Q2-
receptor expressed in human embryonic kidney (HEK) 293
cells in vitro [6,7]. Since a homologous histidine residue also
occurs in the K2-, K3- and K5-subunits (Fig. 1), we investi-
gated whether the histidine to arginine mutation would rep-
resent a common molecular switch to render the respective
receptor subtypes diazepam-insensitive. A common molecular
switch could be exploited for the analysis of the contribution
of individual receptor subtypes to the pharmacological spec-
trum of diazepam by generating knock-in mice carrying this
point mutation. In the present study, the BZ-responsiveness of
point-mutated receptors was tested electrophysiologically fol-
lowing the co-expression of the mutated K1-, K2-, K3- and K5-
subunits with the wild-type L2- (or L3-) and Q2-subunits in
HEK 293 cells.
2. Materials and methods
2.1. Construction of GABAA receptor subunit expression vectors
The rat K1-subunit cDNA [6] (1.6-kb XhoI fragment in XhoI site of
pSK-K1) was subcloned as a HindIII/KpnI fragment into M13mp19
and point-mutated using the Amersham Sculptor kit and oligonucleo-
tide UR39: 5P-GAC TTT TTT CCA TTC CGG AAA AAT GTA
TCT-3P. The mutated cDNA was resequenced, subcloned ¢rst into
pKS (HindIII/KpnI), then with a complete BglII and partial BamHI
digest into the BamHI site of the expression vector pBC12/CMV [8].
The K2-cDNA (1.4-kb fragment in M13PICH-rK2) underwent olignu-
cleotide-directed mutagenesis with KL4: 5P-TGA CTT TTT CCC
GTT CCG GAA GAA GGT GTC AGG AGT-3P, and was rese-
quenced and subcloned as a BamHI/BglII fragment into the BamHI
site of pBC12/CMV. The K3-cDNA [9] (3.4-kb EcoRI fragment in
M13mp18) was mutated using oligonucleotide UR40: 5P-AGA TAC
CTT CTT CCG GAA CGG TAA AAA ATC-3P. The mutated cDNA
was sequenced and subcloned into pKS with SacI (now as a 1.7-kb
fragment). From there it was partially digested with SstI and com-
pletely with BamHI and subcloned into pSP72 (Promega), from where
it was recovered as a BamHI/BglII fragment and subcloned into the
BamHI site of pBC12/CMV. The K5-cDNA [9] (EcoRI partial frag-
ment in M13PIC-19H) was mutated using oligonucleotide UR41: 5P-
GAC TTC TTC CCA TTC CGG AAG AAT GTG TCT-3P, se-
quenced and subcloned into pKS as a 2.1-kb HindIII/SstI fragment.
It was then subcloned into pSP72 with SstI/Asp718, from where it was
recovered as a BamHI/BglII fragment and subcloned into the BamHI
site of pBC12/CMV. Corresponding expression vectors containing the
wild-type K1-, K2-, K3- and K5-subunit cDNAs were prepared in par-
allel. The L2-, L3- and Q2-subunits were also used in pBC12/CMV.
2.2. Cell culture and transfection
Human embryonic kidney cells 293 were grown in MEM medium
supplemented with 10% fetal bovine serum, 50 Wg/ml gentamicin and
20 mM L-glutamine (all from Life Technologies, Basel, Switzerland)
and transformed transiently with rat cDNA KLQ combinations (ratio
1:1:1) by calcium phosphate precipitation [10].
2.3. Electrophysiology and data analysis
The whole-cell con¢guration of the patch-clamp technique was used
to record GABA-induced Cl3 currents. The GABA dose-response
curves were obtained by applying 2-s pulses of GABA every 2 min
to the patch-clamped HEK-293 cells, using a multibarrelled micro-
applicator pipette, as previously described [11]. The maximum current
amplitudes from individual cells were ¢rst ¢tted separately using the
equation I/Imax = 1/(1+(EC50/[GABA])Hill), where I = GABA-evoked
current, Imax = the maximum of the ¢t, EC50 = the GABA concentra-
tion evoking the half maximal response, and Hill = the Hill coe⁄cient.
The individual dose-response curves were then normalized to Imax,
and the data replotted using the mean values for each concentration.
For each experiment, at least three GABA control responses were
evoked and only cells showing stable GABA responses were selected
for the drug testing. Prior to microapplication of a GABA-drug mix-
ture, the same concentration of the drug alone was applied by bath
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perfusion for at least 2 min. Stock solutions of the test compounds
were prepared in 100% DMSO and diluted 1000-fold before use. Dur-
ing the experiment, all bath solutions contained 0.1% DMSO, which
by itself was without detectable e¡ect on the GABA responses. The
benzodiazepine ligands bretazenil, Ro 15-4513, and diazepam were
kindly provided by F. Ho¡mann-La Roche Ltd. (Basel).
3. Results
3.1. GABA-sensitivity of the point-mutated recombinant
GABAA-receptors
A histidine to arginine codon substitution was introduced
into homologous positions of rat K1-, K2-, K3- and K5-subunit
cDNAs (positions 101, 101, 126 and 105, respectively) (Fig. 1)
by site-directed mutagenesis. The wild-type and point-mutated
K-subunits were co-expressed in HEK 293 cells with the Q2-
subunit and either the L2- or the L3-subunit, depending on the
associations most commonly detected in rat brain [12^14], in
order to generate the following subunit combinations:
K1L2Q2, K1H101RL2Q2, K2L3Q2, K2H101RL3Q2, K3L3Q2,
K3H126RL3Q2, K5L2Q2 and K5H105RL2Q2.
The EC50 values for GABA for the receptors incorporating
wild-type K-subunits were 23 þ 2 WM for K1L2Q2, 74 þ 12 WM
for K2L3Q2, 165 þ 68 WM for K3L3Q2 and 14 þ 1 WM for
K5L2Q2 (Fig. 2). These values largely correspond to the po-
tencies of GABA reported previously: the published EC50
values are 4.5^20 WM for K1L2Q2 [15^17], 25 WM for K2L3Q2
[18], and 4.2^16 WM for K5L2Q2 [9,11,15,17]. Only the EC50
value determined for the K3L3Q2 (165 þ 68 WM) di¡ered ap-
preciably from the published values, 28 WM and 33 WM
[17,18]. The GABA EC50 values for receptors incorporating
the point-mutated K-subunits were all modestly higher than
the EC50 values for the wild-type receptors: K1H101RL2Q2
yielding an EC50 value of 31 þ 1 WM (compared to 23 þ 2
WM for K1L2Q2); K2H101RL3Q2 yielding 154 þ 4 WM (compared
to 74 þ 12 WM for K2L3Q2); K3H126RL3Q2 yielding 253 þ 51 WM
(compared to 165 þ 68 WM for K3L3Q2) and K5H105RL2Q2 yield-
ing 27 þ 1 WM (compared to 14 þ 1 WM for K5L2Q2) (Fig. 2).
3.2. Modulation of point-mutated GABAA-receptors by ligands
of the benzodiazepine site
To assess the modulation of the GABA-evoked currents by
benzodiazepine site ligands, GABA concentrations of 3 WM
(K1-, K3- and K5-receptors) and 30 WM (K2-receptor) were
chosen, corresponding to maximally EC30 values. The modu-
lation of the GABA response by the full agonist diazepam is
summarized in Fig. 3; representative individual traces for the
K2L3Q3 subtype are demonstrated in Fig. 4. The benzodiaze-
pine full agonist diazepam (1 WM) potentiated GABA-induced
currents of receptors incorporating wild-type K1-, K2-, K3-
and K5-subunits by 29 þ 11%, 72 þ 5%, 108 þ 29% and
118 þ 19%, respectively (Figs. 3 and 4). In contrast, the
GABA-evoked responses mediated by receptors containing
the point-mutated K1-, K2-, K3- and K5-subunits were diaze-
pam-insensitive (Figs. 3 and 4) at doses that produced max-
imum enhancement at wild-type receptors. These results dem-
onstrate that K2-, K3- and K5-GABAA-receptors can be
rendered diazepam-insensitive by a histidine to arginine point
mutation. Thus, the structure-activity relationship for the in-
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Fig. 1. Alignement of partial N-terminal extracellular sequences of
the rat GABAA-receptor K-subunits (K1^K6) (modi¢ed from [6]).
The conserved histidine residue in the K1-, K2-, K3- and K5-subunits
(positions 101, 101, 126, and 105, respectively) are highlighted. The
K4- and K6-subunits contain an arginine residue at the correspond-
ing positions (99 and 100, respectively).
Fig. 2. GABA dose-response curves for wild-type and point-mutated
GABAA-receptor subtypes expressed in HEK 293 cells transiently
transfected with the cDNAs coding for the wild-type (wt) or mu-
tated K-subunits in combination with the L2- or L3- and Q2-subunits
(K1L2Q2, K1H101RL2Q2; K2L3Q2, K2H101RL3Q2; K3L3Q2, K3H126RL3Q2;
K5L3Q2, and K5H105RL3Q2). The data points and error bars represent
the means and standard errors for the di¡erent GABA concentra-
tions (n = 3^5).
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teraction of diazepam with the BZ site appears to be con-
served among the receptor subtypes tested.
To assess the in£uence of the histidine to arginine point
mutation on the responsiveness to other benzodiazepine site
ligands, the e¡ect of the partial agonist bretazenil was ana-
lyzed. Application of bretazenil (1 WM) to the receptors con-
taining the wild-type K1-, K2-, K3- and K5-subunits character-
istically potentiated the GABA-evoked response, but to a
lesser degree than the full agonist diazepam applied at the
same concentration (K1L2Q2, potentiation: 12 þ 1%; K2L3Q2,
potentiation: 28 þ 6%; K3L3Q2, potentiation: 72 þ 14%; and
K5L2Q2, potentiation: 37 þ 4%) (Figs. 3 and 4). However, ap-
plication of bretazenil (1 WM) to the receptors containing the
point-mutated K-subunits resulted in a potentiation of the
GABA-evoked response that was 2- to 9-fold higher than
that observed for receptors incorporating wild-type K-subunits
(K1H101RL2Q2, potentiation: 107 þ 16%; K2H101RL3Q2, potentia-
tion: 93 þ 15%; K3H126RL3Q2, potentiation: 148 þ 29%, and
K5H105R, potentiation: 239 þ 8%) (Figs. 3 and 4). Bretazenil
thus showed an increased potentiating e¡ect when tested on
the diazepam-insensitive receptors compared to wild-type re-
ceptors. Its potency was about equal to (K2H101RL3Q2,
K3H126RL3Q2) or signi¢cantly higher (K1H101RL2Q2,
K5H105RL2Q2) than that of diazepam (1 WM) at the correspond-
ing wild-type receptors. Thus, the point mutation which ren-
ders the K1-, K2-, K3- and K5-receptors diazepam-insensitive
does not abolish the e¡ectiveness of bretazenil at any of the
receptors.
The partial inverse agonist Ro 15-4513 is known to reduce
the amplitude of the GABA-evoked responses at K1L2Q2,
K1L1Q2, K2L1Q2, K5L3Q2 and K5L3Q3 receptors [19^22]. Here,
we show that the inverse agonism of Ro 15-4513 extends to
the K2L3Q2-, K3L3Q2-, and K5L2Q2-receptors (Figs. 3 and 4).
However, on receptors containing the point-mutated K1-, K2-,
K3- and K5-subunits, Ro 15-4513 (1 WM) was found to
strongly potentiate the GABA-evoked currents. The percent
enhancement of the GABA-evoked currents by Ro 15-4513
applied to the point-mutated receptors (K1L2Q2, potentiation:
171 þ 45%; K2L3Q2, potentiation: 124 þ 6%; K3L3Q2, potentia-
tion: 168 þ 17%; K5L2Q2, potentiation: 124 þ 16%) was equal
to (K5) or greater than (K1, K2, K3) the potentiation induced
by the same dose of diazepam applied to the wild-type recep-
tors (Figs. 3 and 4). The point mutation thus changed the
mode of interaction of Ro 15-4513 from inverse agonism to
agonism. These results suggest that the mode of interaction of
Ro 15-4513 with the benzodiazepine binding site di¡ers from
that of either diazepam and bretazenil.
A switch in the apparent e⁄cacy of a benzodiazepine site
ligand has previously been observed for methyl-6,7-dimeth-
oxy-4-ethyl-L-carboline-3-carboxylate (DMCM), based, how-
ever, on an unusual dose-response behavior on various wild-
type receptors (K1L1Q2, K1L2Q2, and K5L2Q2); DMCM acted
as an inverse agonist at low doses and as an agonist at high
doses [9]. To exclude the possibility that the agonism observed
for Ro 15-4513 on the point-mutated receptors is due to a
dose-response phenomenon, an entire dose-response curve
was recorded for the e¡ect of Ro 15-4513 on one of the
mutant receptors, K2H101RL3Q2 (Fig. 5). For each dose tested
over the range of 1 nM to 1 WM, Ro 15-4513 displayed an
agonistic e¡ect on the mutated receptors. Thus, the agonistic
activity of Ro 15-4513 on receptors containing the mutated K-
subunits cannot be attributed to a dose-response phenomen-
on. The histidine to arginine mutation in the K1- K2-, K3- and
K5-subunits rather switches the e⁄cacy of Ro 15-4513 from
inverse agonism to agonism.
4. Discussion
The BZ binding site is considered to be located at the inter-
face of the K- and the Q2-subunit of the GABAA receptor
(reviewed in [23]). Here we demonstrate that the histidine
residue in the BZ site, originally identi¢ed in the K1-subunit
as a photoa⁄nity target [24,25], is a functional characteristic
common to all major BZ-sensitive GABAA-receptors. Muta-
tion of this residue to arginine in either the K1-, K2-, K3- or
the K5-subunit leads to a complete loss of potentiation of
GABA-induced currents by diazepam when co-expressed
with L2- or L3- and Q2-subunits, in accordance with the dia-
zepam-insensitivity of the K4L2Q2 and K6L2Q2 wild-type recep-
tors which contain an arginine residue in the corresponding
position [19,26^28]. Since diazepam does not bind to either
the K4- and K6-receptors [26,27,29] or the K1H101RL2Q2-recep-
tors [6], the lack of diazepam-responsiveness of the point-mu-
tated K2-, K3- and K5-receptors can most likely be attributed
to a lack of a⁄nity for diazepam.
In contrast to diazepam, the potentiation of GABA-evoked
responses of the point-mutated receptors by bretazenil is uni-
formly increased compared to the respective wild-type recep-
tors. This is unlikely to be due to an increase in the a⁄nity of
bretazenil, since bretazenil displays a nanomolar a⁄nity to the
diazepam-insensitive K6L3Q2-receptor (Ki = 12.7 nM) which is
lower than its a⁄nity to the diazepam-sensitive K1L3Q2-recep-
tor (Ki = 0.35 nM) [27]. Thus, the histidine to arginine point
mutation does not appear to increase the a⁄nity but rather to
a¡ect the signal transduction process in the interaction be-
tween bretazenil and the mutant receptors. These di¡erences
in the interaction of diazepam and bretazenil appear to be
common to all receptor subtypes tested and point to distinct
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Fig. 3. Potentiation of the GABA-evoked currents by BZ site li-
gands for wild-type and point-mutated GABAA-receptor subtypes
expressed in HEK 293 cells transiently transfected with the cDNAs
coding for the wild-type (wt) or mutated K-subunits in combination
with the L2- or L3- and Q2-subunits (for details see legend to Fig.
2). The modulation of GABA-evoked currents by the BZ site li-
gands diazepam (1 Wm), bretazenil (1 Wm) and Ro 15-4513 (1 Wm) is
expressed relative to the control currents at the given GABA con-
centration (mean þ standard error, n = 3^7).
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domains for interaction of diazepam and bretazenil at the BZ
binding site.
The inverse agonist Ro 15-4513 interacts in yet another
manner with the benzodiazepine binding site of GABAA-re-
ceptors. In the point-mutated receptors, its e⁄cacy is switched
from inverse agonism to agonism. This is in line with the
agonistic action of Ro 15-4513 on the diazepam-insensitive
K4- or K6-subunit-containing receptors K4L1Q2, K4L2Q2,
K6L1Q2 and K6L2Q2 [19,26^28] and the retention of its high
a⁄nity to the diazepam-insensitive K6-receptors (KD=10 nM)
[6]. Ro 15-4513 has previously been shown to act as a partial
agonist at K1L1Q2-receptors containing a threonine to serine
substitution in position 142 of the Q2-subunit [21]. Therefore,
critical residues in both the K-subunits and the Q2-subunit
determine the e⁄cacy of Ro 15-4513.
In summary, the mutation of a single histidine to arginine
in the K1- K2-, K3- and K5-subunits induces a conformational
change with distinct pharmacological consequences common
to all GABAA-receptors tested. The results underline the no-
tion that the GABAA-receptor subtypes contain common and
highly conserved structural determinants in£uencing the a⁄n-
ity and e⁄cacy of BZ site ligands.
Our ¢ndings open the possibility to de¢ne the pharmaco-
logical signi¢cance of GABAA-receptor subtypes in vivo. By
individually mutating the conserved histidine residue in the
K1-, K2-, K3- and K5-subunits to arginine by gene targeting,
individual GABAA-receptor subtypes will be rendered insen-
sitive to diazepam. The resulting mouse lines are expected to
display characteristic de¢cits in the pharmacological spectrum
of diazepam. The present results support the validity of this in
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Fig. 4. Single traces of the e¡ects of diazepam (DIAZ), bretazenil (BRET) and Ro 15-4513 on the GABA-evoked currents are exempli¢ed for
wild-type K2L3Q2 and point-mutated K2H101RL3Q2 GABAA-receptors. In K2L3Q2-receptors the agonist diazepam (1 Wm) and to a lesser degree
the partial agonist bretazenil (1 Wm) potentiated the current, while the inverse agonist Ro 15-4513 (1 Wm) reduced the current. In K2H101RL3Q2
receptors, diazepam was without e¡ect and the current was strongly potentiated by bretazenil and Ro 15-4513.
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vivo approach by verifying three major preconditions. (i) The
point mutation a¡ects the diazepam response at the corre-
sponding four GABAA-receptor subtypes in the same manner.
(ii) The mutation does not appreciably a¡ect the potency of
GABA in activating the four receptor subtypes, suggesting
that the physiological responsiveness of the receptors to
GABA is not altered. (iii) The mutation does not interfere
with subunit synthesis and assembly, which is in keeping
with the expression of diazepam-insensitive K4- and K6-recep-
tors in the brain. The point-mutated mouse lines will provide
important insights into the neuronal circuits mediating selec-
tive actions of diazepam-induced behavior.
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Fig. 5. Dose-response curve for the e¡ect of Ro 15-4513 on the re-
combinant K2H101RL3Q2 receptor-mediated current evoked by 30 WM
GABA. The mean amplitudes of the potentiated currents relative to
the control currents were normalized to a control value set at 1.0,
and plotted as a function of the drug concentration. The data
points and error bars represent the means and standard errors for
di¡erent drug concentrations (n = 3^4).
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